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Randomised trial of oral versus sequential intravenous/oral
cephalosporins in children with pyelonephritis
Abstract
The hypothesis was tested that oral antibiotic treatment in children with acute pyelonephritis and
scintigraphy-documented lesions is equally as efficacious as sequential intravenous/oral therapy with
respect to the incidence of renal scarring. A randomised multi-centre trial was conducted in 365 children
aged 6 months to 16 years with bacterial growth in cultures from urine collected by catheter. The
children were assigned to receive either oral ceftibuten (9 mg/kg once daily) for 14 days or intravenous
ceftriaxone (50 mg/kg once daily) for 3 days followed by oral ceftibuten for 11 days. Only patients with
lesions detected on acute-phase dimercaptosuccinic acid (DMSA) scintigraphy underwent follow-up
scintigraphy. Efficacy was evaluated by the rate of renal scarring after 6 months on follow-up
scintigraphy. Of 219 children with lesions on acute-phase scintigraphy, 152 completed the study; 80 (72
females, median age 2.2 years) were given ceftibuten and 72 (62 females, median age 1.6 years) were
given ceftriaxone/ceftibuten. Patients in the intravenous/oral group had significantly higher C-reactive
protein (CRP) concentrations at baseline and larger lesion(s) on acute-phase scintigraphy. Follow-up
scintigraphy showed renal scarring in 21/80 children treated with ceftibuten and 33/72 with
ceftriaxone/ceftibuten (p = 0.01). However, after adjustment for the confounding variables (CRP and
size of acute-phase lesion), no significant difference was observed for renal scarring between the two
groups (p = 0.2). Renal scarring correlated with the extent of the acute-phase lesion (r = 0.60, p <
0.0001) and the grade of vesico-ureteric reflux (r = 0.31, p = 0.03), and was more frequent in refluxing
renal units (p = 0.04). The majority of patients, i.e. 44 in the oral group and 47 in the intravenous/oral
group, were managed as out-patients. Side effects were not observed. From this study, we can conclude
that once-daily oral ceftibuten for 14 days yielded comparable results to sequential
ceftriaxone/ceftibuten treatment in children aged 6 months to 16 years with DMSA-documented acute
pyelonephritis and it allowed out-patient management in the majority of these children.
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Abstract 
The hypothesis was tested that oral antibiotic treatment in children with acute pyelonephritis 
and scintigraphy-documented lesions is equally efficacious as sequential intravenous/oral 
therapy with respect to the incidence of renal scarring. A randomised multi-centre trial was 
conducted in 365 children aged 6 months to 16 years with bacterial growth in cultures from 
urine collected by catheter. The children were assigned to receive either oral ceftibuten (9 
mg/kg once daily) for 14 days or intravenous ceftriaxone (50 mg/kg once daily) for 3 days, 
followed by oral ceftibuten for 11 days. Only patients with lesions detected on acute-phase 
dimercaptosuccinic acid (DMSA) scintigraphy underwent follow-up scintigraphy. Efficacy 
was evaluated by the rate of renal scarring after 6 months on follow-up scintigraphy. Of 219 
children with lesions on acute-phase scintigraphy, 152 completed the study: 80 (72 females, 
median age 2.2 years) were given ceftibuten, 72 (62 females, 1.6 years) 
ceftriaxone/ceftibuten. Patients in the intravenous/oral group had significantly higher CRP 
concentrations at baseline and larger lesion(s) on acute-phase scintigraphy. Follow-up 
scintigraphy showed renal scarring in 21/80 (26%) children treated with ceftibuten and 33/72 
(46%) with ceftriaxone/ceftibuten (p=0.01). However, after adjustment for the confounding 
variables (CRP and size of acute-phase lesion), no significant difference was observed for 
renal scarring between the two groups (p=0.2). Renal scarring correlated with the extent of the 
acute-phase lesion (r=0.60, p<0.0001) and the grade of vesico-ureteric reflux (r=0.31, p=0.03) 
and was more frequent in refluxing renal units (p=0.04). The majority of patients, i.e., 55% in 
the oral and 66% in the intravenous/oral group, were managed as outpatients. Side effects 
were not observed. Conclusions: Once daily oral ceftibuten for 14 days yielded comparable 
results as sequential ceftriaxone-ceftibuten treatment in children aged 6 months to 16 years 
with DMSA-documented acute pyelonephritis and allowed outpatient management in the 
majority of these children. 
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Introduction 
In infants and young children, upper and lower urinary tract infections are common [1], and a 
febrile urinary tract infection is considered to be an upper urinary tract infection (i.e., 
pyelonephritis). Up to two thirds of children with acute pyelonephritis show a lesion (defect) 
on technetium-99m-labelled dimercaptosuccinic acid (DMSA) scintigraphy during the acute 
phase [5, 14, 21, 25]. Only these children develop post-infectious renal scarring, and the 
incidence is 29–60% [5, 15, 21, 24, 30, 35]. Long-term follow-up of children with renal 
scarring showed a significant reduction of renal function [20, 32, 33]. In contrast, children 
with a febrile urinary tract infection without lesion on acute-phase DMSA-scintigraphy did 
not develop renal scarring [14, 15, 30]. 
 Although the recommended initial treatment for infants and young children with 
pyelonephritis is the intravenous administration of antibiotics [1, 5, 6, 8], we hypothesised 
that oral antibiotics are as efficacious as sequential intravenous/oral treatment  with respect to 
the incidence of renal scarring 6 months after acute pyelonephritis with scintigraphy-
documented acute lesions. Several lines of evidence support our hypothesis. The prevalence 
of bacteraemia in pyelonephritis is 6.1–22.7% in infants younger than 2 months of age [7, 25] 
and 9.3% in infants younger than 6 months [2]. In contrast, children older than 6 months of 
age either never have bacteraemia [2] or only rarely show bacteraemia [25]. Thus, oral 
 4 
antimicrobial therapy of acute pyelonephritis appeared a safe option, particularly for children 
older than 6 months of age. Indeed, the results from two prior prospective trials suggested that 
acute pyelonephritis in children could be treated with oral antibiotics [14, 21]. Two additional 
aspects need consideration. First, it has to be shown that the oral route is as efficacious as the 
parenteral route also in patients at highest risk for renal scarring, i.e., children with systemic 
inflammation (high C-reactive protein (CRP)) and initial scintigraphic lesions. Second, oral 
treatment might allow full outpatient management with major benefits to patients and parents. 
Ceftibuten, an oral cephalosporin, was deliberately chosen for three reasons: (i) good 
antimicrobial activity, (ii) lack of resistance against pathogens of community-acquired urinary 
tract infection and (iii) its long half-life allowing once daily oral dosing [4, 19, 23, 34].  
 To test our hypothesis, we conducted a prospective randomised controlled multi-centre 
trial to compare the effect of oral treatment with once daily ceftibuten for 14 days with the 
effect of the sequential intravenous/oral regimen (3-day intravenous treatment with 
ceftriaxone, followed by 11 days with oral cephalosporin) [5]. Where it was in accordance 
with the local hospital guidelines, patients were planned to be treated as out-patients, as oral 
and outpatient management might reduce the burden on hospital staff and costs. Only children 
older than 6 months of age with acute pyelonephritis and acute lesions on DMSA scintigraphy 
[10, 11, 29] – those at highest risk for sequelae, i.e., renal scarring – were included.. 
Methods 
Five Swiss paediatric hospitals collaborated in a prospective, investigator-initiated clinical 
trial to compare the effects of oral and sequential intravenous/oral antibiotic regimens in 
children with pyelonephritis and acute lesions on DMSA scintigraphy. Patients were recruited 
from 1 July 2001 to 30 April 2004, and follow-up ended on 31 December 2004. The study 
was approved by the national agency for therapeutic products (Swissmedic) and the local 
ethical committees of all participating centres. Written informed consent was obtained from at 
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least one parent of each patient. The study was carried out independently of the financial 
supporter. Financial industry support for central collection and analysis of data was sought 
only after the study had been approved by the national and local authorities. 
Patient recruitment 
Patients, aged 6 months to 16 years, with acute community-acquired pyelonephritis treated at 
the University Children’s Hospitals of Zurich, Geneva, and Basle, or in the departments of 
paediatrics of the hospitals of Winterthur and Zurich-Triemli, were eligible. Laboratory tests 
on admission included blood count, CRP, plasma creatinine, blood cultures, urinary dipstick 
and/or microscopic urinalysis (cell count in non-centrifuged urine), and urine culture. The 
urine samples were collected by bladder catheterisation. Diagnosis of acute pyelonephritis 
was considered probable in children with fever (rectal temperature >38°C or axillary 
temperature >38.5°C), an abnormal urinary dipstick test (leukocyte esterase ≥1+, or nitrite 
positive), or microscopic urinalysis (pyuria with ≥10 white blood cells/µl), and serum CRP 
concentration >10 mg/l (normal <4mg/l). Additional clinical signs were not mandatory (e.g., 
abdominal or flank pain in children old enough to report pain accurately, irritability, vomiting, 
diarrhoea, or feeding problems in infants). Positive urine culture was defined as growth ≥104 
colony forming units/ml of a single bacterium. Patients known to have isolated vesico-ureteric 
reflux (VUR), megaureter, or duplex kidney, independently of antibiotic prophylaxis (e.g., 
cotrimoxazole, trimethoprim or nitrofurantoin) were also included. Exclusion criteria were 
age <6 months, antibiotic pre-treatment of acute infection, other abnormalities of the urinary 
tract, known impaired renal function, patients on immunosuppressive therapy, and known 
hypersensitivity to cephalosporins. Patients were also excluded at the discretion of the treating 
physician, if the clinical condition suggested septicaemia or if other reasons precluded oral 
treatment. 
Randomisation 
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Each centre was provided, as many times as necessary, with blocks of 24 sealed envelopes 
containing an equal number of assignments for the two antibiotic regimens. A statistician 
provided the computer-generated code and an independent clerk sealed and bundled the 
opaque envelopes, so that the person enrolling the patient into the study would not have 
known the patient’s assignment. Patients were locally randomised at the time of admission. 
For practical reasons, all patients with a presumed clinical diagnosis of probable 
pyelonephritis were randomised at their first consultation in the emergency unit (i.e., before 
the results of urine culture and DMSA scintigraphy were available). Thus, stratification for 
potentially confounding variables (e.g., grade of inflammation (CRP), size of lesion on acute-
phase DMSA scintigraphy and presence/grade of VUR) was not done. Only patients with 
acute pyelonephritis and lesions on acute-phase scintigraphy, as assessed by the treating 
physicians, underwent a follow-up scintigraphy. 
Antimicrobial therapy and prophylaxis 
Antibiotic therapy was started immediately after urine and blood samples had been analyzed. 
For the “oral-only group,” patients received 9 mg/kg body weight of ceftibuten [34] (Cedax, 
Essex, Lucerne, Switzerland; in Switzerland licensed for children ≥6 months of age) orally 
twice on the first day and once daily thereafter for 14 days. In the “intravenous/oral group,” 
patients received 50 mg/kg ceftriaxone (Rocephin, Roche, Basle, Switzerland) intravenously 
once daily for 3 days and then 9 mg/kg body weight of ceftibuten orally for 11 days. 
Ceftibuten is commercially available in most European countries and in the US. 
 Before starting the clinical study, the antimicrobial susceptibility of Gram-negative 
bacteria, isolated from positive urine cultures consecutively collected from in-patients and 
out-patients at one centre (University Children’s Hospital Zurich), was tested. Of 285 Gram-
negative bacterial isolates, 243 were sensitive to ceftibuten and ceftriaxone; only 
Pseudomonas aeruginosa (n =27) and Enterobacter cloacae (n = 15), two unusual pathogens 
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in community-acquired pyelonephritis, were resistant. Only 63% and 41% of the isolates were 
sensitive to amoxicillin/clavulanic acid and amoxicillin, respectively. 
 Deviation from the assigned antimicrobial treatment regimen was permitted in the 
following events: (i) clinical deterioration as assessed by the treating physician, (ii) presumed 
side-effects of the study drugs, (iii) resistance of bacteria grown in initial urine culture to the 
study antibiotics, and (iv) bacterial growth on follow-up urine culture on days 3–4. 
 All patients were followed at each study centre at least until day three; patients with 
persistent fever at day three were followed until defervescence. The patients were then 
followed clinically by their local paediatrician who informed the study centres in case of 
recurrent urinary tract infection. At the end of the 14-day treatment, antibiotic prophylaxis 
was started either with cotrimoxazole (12–18 mg per kg body weight in one or two doses 
daily) or nitrofurantoin (1–1.5 mg per kg body weight in one or two doses daily) according to 
the Swiss guidelines [13] and was discontinued only if voiding cystourethrography showed 
neither VUR nor other malformations of the urinary tract.  
Outcome measures 
Urine culture and serum CRP were repeated on days 3–4 of treatment. Renal ultrasound was 
done within 24 hours whereas renal DMSA scintigraphy was performed within 5 days as the 
nuclear medicine department does not offer DMSA scan 7 days a week. Thus, some minor 
lesions might become invisible between onset of antibiotic therapy and scan, leading to false 
negative DMSA scintigraphy. Of the children enrolled only those with lesions on acute-phase 
scintigraphy were followed with a second scintigraphy (see below). Investigations were 
completed 2–8 weeks after the acute episode by voiding cystourethrography (at least two 
fillings were performed) to detect VUR (grade I–V). Specimens for urine culture were 
obtained at the voiding cystourethrography and when the children had fever or symptoms of 
urinary tract infection. Study patients were followed at voiding cystourethrography and after 6 
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months at follow-up scintigraphy. Parents were asked whether their child had had fever or 
recurrence of urinary tract infection and whether the prophylaxis had been given as 
prescribed. In addition, safety and convenience of treatment were evaluated in terms of 
discontinuation of therapy and incidence of side effects.  
 The primary end point was – only in patients with lesions on acute-phase scintigraphy 
– the development of renal scarring in both groups (oral and intravenous/oral) after at least 6 
months, documented by follow-up DMSA scintigraphy. The 6-month interval between the 
acute-phase and follow-up scintigraphy was chosen because acute pyelonephritic defects can 
persist for up to 5 months [16]. Secondary end point was the effect of VUR on the 
development of renal scarring. 
Renal DMSA scintigraphy 
Scintigraphy was performed 3 hours after intravenous injection of 99mTc-DMSA 
(Mallinckrodt Medical B.V., Petten, Netherlands). The administered dose was weight-
adjusted, according to the recommendations of the Pediatric Committee of the EANM 
(http://www.eanm.org/scientific_info/guidelines/gl_paed_dmsa_scin.php?navId=54) with a 
minimal dose of 15 MBq and a maximal dose of 100 MBq. Two (one anterior and one 
posterior view) to six views (one anterior, one posterior, two posterior oblique and two 
anterior oblique views) were obtained, but tomography was not systematically performed. 
Each kidney (i.e., renal unit) was assessed separately. Images were acquired on dual-head 
gamma cameras (Zurich: Body Scan, Siemens, Erlangen, Germany; Zurich-Triemli: Prism 
2000 XP with pinhole collimator, Philips (former Picker), Eindhoven, Netherlands; 
Winterthur: E Cam, Siemens, Erlangen, Germany; Basel: Axis, Philips, Eindhoven, 
Netherlands) or a triple-head gamma camera (Geneva: Toshiba GCA-9300 A/HG, Toshiba 
Medical Systems, Tokyo, Japan). 
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 Two paediatric nuclear medicine experts, unaware of the treatment assigned to the 
patients, interpreted independently all initial and follow-up scintigraphies. Disagreements 
were resolved by joint evaluation. Progression of renal lesions was assessed by topographic 
analysis of each lesion. Renal scars in the follow-up scintigraphy were defined as persistent or 
partially reversible lesions at the same location of the lesion in the acute-phase scintigraphy. 
The relative size of each lesion was estimated by relating the surface of the lesion to the 
surface of the kidney, in the view of the scintigraphy where the size of the lesion was most 
pronounced. The grading of the size of the lesion(s) was as follows: Grade 0 = normal, I = 1–
9%, II = 10–24%, III = 25–50% and IV = >50%. 
Statistical analysis 
On the basis of our previous study [5], we estimated that the incidence of renal scarring was 
approximately 35%. This is a non-inferiority trial where a maximal difference of 20% 
between the percentages of renal scarring of the two groups is considered acceptable. For a 
power of 90% and a type 1 error level of 5% (two tailed), the sample size should be 98 
children completing the study in each group; for a power of 80%, the sample size should be at 
least 71 children in each group (Pass 6.0, NCSS, Kaysville, UT, USA). Mann-Whitney U test 
was used for nonparametric comparison between the two groups. Proportions between the 
groups were compared by χ2-test. 
 Despite randomisation, the oral and the intravenous/oral groups showed statistically 
significant differences in CRP concentration at baseline and size of the initial lesion on acute-
phase DMSA scintigraphy. Therefore, to compare proportions between groups, logistic 
regression was used, and the proportions were adjusted for these two confounding variables. 
Spearman rank correlation was calculated between the size of renal scarring and the CRP 
concentration at baseline, the size of lesion on acute-phase scintigraphy, and the grade of 
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VUR. A p-value <0.05 was considered statistically significant. (Software: S-Plus 7.0 for 
Windows, Insightful, Seattle, WA).  
Competing interest and the role of the funding source 
The two corresponding authors applied for financial support of the Essex Company and 
signed the contract; all other authors have no competing interest. The study sponsor had no 
role in (i) study design, (ii) collection, analysis and interpretation of the data, (iii) writing the 
report, and (iv) submission of the manuscript for publication.  
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Results 
Patient data 
A total of 365 patients were randomised (Figure 1). No acute-phase scintigraphy was 
available for 19 (5%) patients, and they were excluded. Consent was withdrawn in 17 
patients, including one patient in the oral group with a protocol deviation. Two further 
patients were excluded due to protocol violation: one was given cefixime instead of 
ceftibuten, and the other was administered medication only after day 3. 
 Acute-phase DMSA scintigraphy was performed in 346 patients: 219 patients (63%) 
showed one or more lesions and were planned to have follow-up scintigraphy. Of these, 67 
patients (31%) had no secondary scintigraphy and did not complete the study, including four 
patients who deviated from the assigned antimicrobial regimen for medical reasons and nine 
patients undergoing a subsequent operation (for details, see “Patients not completing the 
study”). Under the study protocol, 127 patients with normal acute-phase scintigraphy had no 
follow-up. 
 The cohort completing the study with follow-up scintigraphy consisted of 152 patients 
with acute pyelonephritis and lesions on acute-phase scintigraphy. There were 80 patients in 
the oral group and 72 patients in the intravenous/oral group (Figure 1). The clinical and 
laboratory characteristics at baseline (Table 1) and the prevalence of VUR (Table 2) did not 
significantly differ between the two groups, except for serum CRP concentration at baseline 
(p=0.04). All patients had either an abnormal urinary dipstick test or pyuria with ≥10 white 
blood cells/µl. Plasma creatinine was normal in all participants. Escherichia coli were the 
predominant isolated pathogen (137/152: 90%); Proteus spp, Klebsiella pneumoniae, and 
Enterococcus spp. were isolated in only a few cases (Table 1). All isolated bacteria except 
Enterococcus spp. were sensitive to both ceftibuten and ceftriaxone. 
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 The clinical course was comparable in both groups (Table 1): By day 3 approximately 
90% of the patients were afebrile and CRP levels decreased to about 60% in both groups; 
seven and eight patients from the oral and intravenous/oral group, respectively, had persistent 
fever. In two of them (both from the oral group) the general condition did not improve, and 
therapy was switched to intravenous treatment with amoxicillin/clavulanic acid and 
ceftriaxone. One patient in the intravenous/oral group had E. coli bacteraemia; the clinical 
course was uneventful without changing the therapeutic regimen. Urine culture grew 
cephalosporin-resistant Enterococcus spp. in three patients in the intravenous/oral group: At 
day 3, the urine was sterile in all of them, and two patients were afebrile. Thus, antimicrobial 
therapy was not changed. Urine cultures obtained from every patient on days 3–4 of treatment 
were all sterile. Both antimicrobial regimens were well tolerated, and no side effects (e.g., 
skin rash, diarrhoea and gall or kidney stones) were observed. 
 All 92 patients (61% of the study cohort) at the University Children’s Hospitals Zurich 
and Geneva were treated as out-patients. The majority of patients from the other centres were 
hospitalised for an average of 3 days.  
Acute-phase DMSA scintigraphy 
Eight patients from each group had acute-phase bilateral lesions, resulting in 88 and 80 
affected renal units in the oral and intravenous/oral group, respectively (Table 3). In the 
majority of renal units, the size of the acute lesion was grade I or II. Extensive lesions (grade 
III and IV) were less frequent in the oral group than in the intravenous/oral group (11/160 vs. 
22/144 renal units; p=0.03; χ2-test).  
Renal scarring on follow-up DMSA scintigraphy 
Among the 152 children, 54 developed renal scarring, including 21 patients  from the oral 
group and 33 (46%) from the intravenous/oral group (Table 3). Among patients with bilateral 
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acute-phase lesions, none from the oral group, but three of eight patients from the 
intravenous/oral group developed bilateral scars. All scars were localised to the site of the 
acute-phase lesion(s). Renal scarring correlated with the size of the acute renal lesion (r=0.60, 
p<0.0001; Table 3). After statistical adjustment for the two confounding variables (i.e., CRP 
concentration at baseline and size of acute-phase scintigraphic lesion), there was no 
significant difference between the percentages of renal scarring in the two groups, either 
expressed per patient or per renal unit (adjusted p-values; Table 3). All three patients from the 
intravenous/oral group with Enterococcus spp. whose urine had became sterile at day 3, and 
both patients from the oral group with protocol deviation developed renal scarring. 
 The prevalence of VUR did not significantly differ between the two groups. VUR was 
present in 93 (31%) of 304 renal units with grade I–II, III, and IV in 71, 15, and 7 units, 
respectively (table 2). Scarring in patients with unilateral VUR was always restricted to the 
refluxing unit. The correlation between VUR and renal scarring was analysed in a double 
manner (Table 4). If VUR and scarring were expressed per patient, renal scarring was not 
significantly different in patients with and without VUR. However, if VUR and scarring were 
analysed per renal unit, scarring was more frequent in refluxing units (p=0.04; χ2-test). In 
addition, scarring was correlated with the grade of VUR (r=0.31, p=0.03): All seven renal 
units with grade IV VUR developed scars, and renal units with grade III or IV VUR (11/22; 
50%) had significantly more scarring compared to renal units with grade I-II VUR (16/71; 
23%: p=0.02; χ2-test). 
 The frequency of renal scarring was not different between infants <1 year (14/46) and 
older children (40/106). In addition, the frequency of renal scarring did not differ between the 
two centres conducting out-patient management only and the three centres with in-patient 
management (Table 5). In addition, there was no difference in the frequency of scarring 
among the five recruitment centres (data not shown). 
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 Urinary tract infection was reported in 27 patients (18%) before entry into the study, 
though it was not specified as cystitis or pyelonephritis (Table 1). Three of 14 patients from 
the oral group showed renal scarring, compared with seven of 13 patients from the 
oral/intravenous group. Six patients had a recurrent febrile urinary tract infection between the 
acute-phase and follow-up scintigraphy. Both patients from the oral group had no scarring. In 
contrast, all four patients from the intravenous/oral group had scars at the same location as the 
lesions on acute-phase scintigraphy. As it is difficult, if not impossible to distinguish between 
fresh lesions and old scars, additional analysis was undertaken after exclusion of the 33 
patients with previous or recurrent pyelonephritis. Renal scarring was not significantly 
different between the patients in the oral group (18/64) and in the intravenous/oral group 
(22/55; p = 0.17).  
Patients not completing the study 
Of 365 randomised patients, 86 failed to adhere to the protocol and did not complete the 
study: 19 patients had no acute-phase scintigraphy, and 67 patients with lesions on acute-
phase scintigraphy had no follow-up scintigraphy (Figure 1). Five patients deviated from the 
assigned treatment regimen for medical reasons. One patient was randomly placed in the oral 
group and switched to intravenous therapy due to recurrent vomiting; acute-phase 
scintigraphy was not performed, but scintigraphy, performed after antireflux surgery 2 years 
later, was normal. Four patients with lesions on acute-phase scintigraphy showed persistent 
fever beyond day 3 without apparent improvement of the general condition: One patient from 
the oral group was switched to intravenous meropenem. Two patients from the 
intravenous/oral group were maintained on ceftriaxone for 7 days. Another patient from the 
intravenous/oral group with Enterococcus spp. in urine culture was switched to 
amoxicillin/clavulanic acid. Parents withdrew consent for follow-up scintigraphy in those four 
patients and in 54 additional patients. Nine patients underwent surgery: ureterocystoneostomy 
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in five patients with VUR, pyeloplasty in three patients with pyeloureteric junction 
obstruction and nephrectomy of a multicystic dysplastic kidney in one patient. None of these 
children had follow-up scintigraphy. 
 In one centre (University Children’s Hospital, Zurich), all eligible patients were 
recorded in a “log book,” and any reasons for refusal or withdrawal were recorded. There 
were 292 children with a febrile urinary tract infection, of whom 40 patients were excluded in 
accordance with the exclusion criteria. Of the 252 eligible study candidates, 125 (50%) could 
not be randomised for two reasons: 65 Swiss patients whose parents did not consent, and 60 
immigrants whose parents had a language barrier rendering informed consent impossible. 
Thus, 127 patients were randomised: 48 patients were not enrolled because no acute-phase 
scintigraphy had been performed (parental withdrawal of consent: n = 10; protocol violation: 
n = 1) or the acute-phase scintigraphy was normal (with bacteriuria: n = 29; with negative 
urine culture: n = 8), 23 patients with acute-phase lesions had no follow-up scintigraphy, and 
56 patients completed the study. 
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Discussion 
This prospective multi-centre randomised trial focussed on children with community-acquired 
acute pyelonephritis and renal lesions on acute-phase DMSA scintigraphy, i.e., patients at risk 
for renal scarring. In patients aged 6 months to 16 years, we showed that oral treatment with 
once daily ceftibuten is safe and equally efficacious with respect to renal scarring after 6 
months when compared with a sequential intravenous/oral regimen.. The oral antimicrobial 
was well-tolerated and side effects, including skin rash, diarrhoea, or gall bladder or kidney 
stones, were not observed. Thus, this study identifies a treatment modality for acute 
pyelonephritis in children that offers the benefits of entire out-patient management. 
 The study was designed to compare the efficacy of oral with sequential 
intravenous/oral antimicrobial treatment for children with pyelonephritis at risk of renal 
scarring. Patients were randomised for the treatment regimen before scintigraphic lesions 
were verified for two reasons: (i)  only children with lesions in acute-phase scintigraphy are 
likely to develop renal scars [14, 15, 30], (ii)  acute-phase scintigraphy cannot be performed 
immediately after diagnosis of acute pyelonephritis. However, to improve the diagnostic 
accuracy of acute pyelonephritis, DMSA scintigraphy is ideally done within two days. In the 
future, magnetic resonance imaging might offer both use of non-ionizing radiation and better 
distinction between acute lesion and scar [18]. 
 The presence of renal scars is a surrogate outcome. Although only a few studies have 
analysed the long-term outcome, renal scars can result in significant sequelae [20, 32, 33]. 
Follow-up of children with renal scarring for 16–26 years after childhood pyelonephritis 
showed a significant reduction of individual glomerular filtration rate in the unilaterally 
scarred kidney [32, 33]. In addition, the long-term outcome at a mean age of 41 years (and 
mean follow-up of 37 years) in children with both pyelonephritis and VUR showed a lowered 
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glomerular filtration rate (83% of patients), hypertension (50%) and proteinuria (25%) in 
patients with bilateral scars [20]. An increased tendency for hypertension was also found in 
patients with unilateral scarring [20]. 
 The proportions of renal scarring in patients (oral group: 26%; intravenous/oral group: 
46%) were comparable with previous scintigraphy investigations that documented renal 
scarring in 29–60% of children after acute pyelonephritis [5, 15, 16, 21, 24, 30, 31, 35]. These 
results indicate that mere oral ceftibuten therapy is as efficacious as parenteral therapy, i.e., a 
3-day or even 10-day course of intravenous antibiotic therapy with respect to renal scarring. 
However, antibiotic therapy either intravenous or oral is not able to prevent renal scarring in a 
substantial proportion of children with pyelonephritis. The percentage of renal scarring in our 
study appeared to be lower in the oral treatment group than in the intravenous/oral group. Yet 
despite randomisation, the two groups differed significantly in the number of patients with 
previous and recurrent infections, CRP concentration at baseline, and the size of the lesion in 
acute-phase scintigraphy. The latter variable has a significant effect on the evolution of renal 
scarring, as observed in our previous study [5]. After adjustment for these confounding 
variables, the final analysis showed a similar frequency of renal scarring in both groups. 
Children aged >1 year did not develop scars more frequently than children <1 year. This is in 
contrast to previous studies, including our own [5, 15, 24]. .  
 There was no significant difference of renal scarring between in-patients and out-
patients in both the oral and the intravenous/oral group. Also taking into consideration that 
allocation to in-patient or out-patient treatment was determined by local hospital guidelines 
and not by randomisation, this finding is valid and reliable as treatment of every patient was 
guided by a defined protocol. Thus, if out-patient treatment is chosen, clinical evaluation and 
urinalysis at day 3 and day 14 are recommended. If the patient is afebrile and urinalysis is 
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normal, routine follow-up urine culture is not mandatory. Oral out-patient management might 
reduce the costs, though this was not formally evaluated here. 
In this study, renal scarring correlated significantly with the VUR per renal unit (but 
not per patient) and the grade of VUR, in particular grade III or IV VUR. Renal scarring in 
patients with unilateral VUR was always restricted to the refluxing unit. Published studies on 
the effects of VUR on renal scarring are controversial: some studies showed a significant 
influence [12, 24, 26], and others did not [5, 22]. There were, however, methodological 
inconsistencies. For example, not all studies discriminated between lower and upper urinary 
tract infection or between VUR per patient and per renal unit.   
 Almost all pathogens isolated in this study of acute community-acquired 
pyelonephritis were E. coli susceptible to cephalosporins. Thus, antimicrobial treatment with 
the chosen cephalosporin is safe. This is of considerable relevance given that the prevalence 
of E. coli resistant to aminopenicillins may be up to 50% [27]. The specific advantage of the 
oral cephalosporin ceftibuten for out-patient management is its once daily oral dosing, based 
on a long T½ with plasma concentrations above minimal inhibitory concentration for >16 
hours; it has an excellent oral bioavailability and 60–70% of the drug is excreted in the urine. 
The recommended dose is 9 mg/kg body weight given once daily [4, 17, 23, 34]. Side effects 
in this and other studies are rare [28, 34], and ceftibuten has been previously examined in 
children with urinary tract infection [3, 31]. Infections with intrinsically cephalosporin-
resistant Enterococcus spp. in this study were rare (4/365; 1%); in three of those the urine was 
sterile on day 3, suggesting a good clinical response and therefore not urging the treating 
physicians to change therapy. Nevertheless, all three patients developed renal scars. Thus, 
patients with acute pyelonephritis treated with a cephalosporin should be switched to 
aminopenicillin upon growth of enterococci in urine cultures.  
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Our results are in agreement with two recent prospective trials that suggested acute 
pyelonephritis can be treated with oral antibiotics. In the study by Montini et al.[21], 
amoxicillin/clavulanic acid was given for 10 days to 135 children aged 1 month to 7 years. 
Renal scarring developed in 26/96 patients (28%) with lesions on acute-phase scintigraphy 
comparable to the 26% found among children with oral treatment in our study and in earlier 
studies [5, 15, 16, 24, 30, 35]. However, the high prevalence of resistance of common urinary 
pathogens against amoxicillin/clavulanic acid in our unit (>30% of E. coli isolates are 
resistant against amoxicillin/clavulanic acid) and many other centres precludes the empiric 
use of this antimicrobial [27]. In the study by Hoberman et al.[14], cefixime was administered 
orally for 14 days to 153 children younger than 2 years. The renal scarring assessed at 6 
months was lower with 16.9% in patients with lesions on acute-phase scintigraphy; these 
patients, however, had mild infection as the mean initial CRP concentration (11.9 mg/l) was 
low. In contrast, median CRP was 100 mg/l in our study, i.e., a 10-fold higher range, 
indicating more pronounced inflammation, which in turn may explain the higher rate of renal 
scarring. Also Montini et al.[21] reported an initial CRP concentration nine-fold above upper 
normal value with a similar range of scarring in children. Nevertheless, by bag urine 
collection they may have included children with false positive urine cultures as urine 
collected by catheter was not a prerequisite for inclusion as in our and the study by Hoberman 
et al [14]. Thus, compared with these two studies, the here reported study included children 
with more severe disease, covered a wider age range, and renal scarring was correlated to 
VUR per renal unit, and most importantly, showed no difference for in- and outpatient 
management, respectively. Overall, given the similar frequencies of renal scarring after oral 
and sequential intravenous/oral antimicrobial treatment in all three studies, the oral only 
regimen appears as an alternative offering the benefits of out-patient management, including 
the avoidance of painful and laborious intravenous approach and reduction of burdens on both 
parents and hospital staff. 
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This study required randomisation and enrolment of a substantially larger number of 
patients than the number of patients eventually qualifying for analysis of renal scarring. In 
agreement with the literature [5, 14, 21, 25] one third of the enrolled patients showed no 
lesions in acute-phase scintigraphy and were subsequently excluded from follow-up analysis 
as they are not at risk of renal scarring [14, 15, 30]. In addition, almost one third of the 
children with lesions in the acute-phase scintigraphy did not undergo follow-up scintigraphy, 
primarily due to withdrawal of parental consent. Although this resulted in a rather 
considerable reduction of the number of eventually eligible patients, skewing of the study 
results is not likely. The drop-outs were evenly distributed among the randomisation groups 
and the participating centres. Nevertheless, the relatively high number of drop-outs recorded 
in this study may mirror the limited willingness of parents and their children to participate in 
prospective clinical trials. In particular, if the study lasts several months beyond the acute 
phase of the illness and resolution of clinical symptoms and includes procedures (e.g., 
injection of radioactive substances, perceived as invasive by some parents).  
A further difficulty of the scintigraphy studies (including the present) is to make the 
distinction between acquired renal scarring and congenital dysplasia in patients with 
persistent photon defect on DMSA scintigraphy [9]. Without exact patient history or previous 
imaging, the aetiology of scars can not always be determined. To limit this bias, renal scarring 
was defined in our study as persistent or partially reversible lesions at the same location of the 
lesion in the acute-phase scintigraphy. In addition, renal ultrasound was not suggestive of 
renal dysplasia in any of the patients. 
 In summary, our hypothesis was validated. Oral antimicrobial therapy with once daily 
ceftibuten for 14 days, with its attendant benefits, was shown to be equally efficacious as 
sequential treatment with intravenous ceftriaxone for 3 days, followed by 11 days of oral 
ceftibuten for pyelonephritis in children.. The optimal duration of antimicrobial therapy, 
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however, and the role of oral regimen in selected children (i.e., <6 months of age or with 
complex urological malformations) [6] remain to be determined. 
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Figure 1. Randomisation and patient flow chart  
Randomisation: n = 365 
Oral: n = 175; intravenous/oral: n = 190 
 
 
       
 
Drop out: No acute-phase scintigraphy: n = 19 
- Oral group: n = 11 
- Intravenous/oral group: n = 8 
n = 17: consent withdrawn, including protocol deviation (n = 1) 
n = 2: protocol violation 
 
 
 
Patients undergoing acute-phase scintigraphy: n = 346 
Oral: n = 164; intravenous/oral : n = 182 
 
 
 
 
 
                     
 
Drop out: Normal acute-phase scintigraphy: n = 127 (37% of 346) 
- Oral group: 54/164 (33%) 
- Intravenous/oral group: n = 73/182 (40%) 
 
 
 
Patiens with lesion on acute-phase scintigraphy: n = 219 (63% of 346) 
Oral: n = 110; intravenous/oral: n = 109 
 
 
 
 
Drop out: No follow-up scintigraphy: n = 67 (31% of 219) 
- Oral group: n = 30 
- Intravenous/oral group: n = 37 
n = 58: consent withdrawn, including protocol deviation (n = 4) 
n = 9: subsequent operation 
 
 
Ultimate study cohort with follow-up scintigraphy: n = 152 (69% of 219) 
Zurich: n = 56 (28: oral – 28: intravenous/oral) 
Geneva: n = 36 (16 – 20) 
Winterthur: n = 32 (19 – 13) 
Zurich-Triemli: n = 20 (12 – 8) 
Basle: n = 8 (5 – 3)  
 
 
 
 
 
 
 
 
Oral group: n = 80 
 
 
 
 
Intravenous/oral: n = 72 
 
Table 1. Baseline characteristics of 152 children with lesions on acute-phase DMSA 
scintigraphy 
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Characteristics Oral group 
n = 80 
Intravenous/oral group 
n = 72 
Sex   
 Male 8 10 
 Female 72 62 
Age (year)   
 Median 2.2 1.6 
 Interquartile range 0.9–4.9 1.0–4.4 
 Whole range 0.5–13.3 0.5–15.8 
Previous urinary tract infections   
 None 66 59 
 ≥ 1 14 13 
Fever (≥38.5° C) before treatment (days)    
 Median 3 2.5 
 Interquartile range 1–4 1–4 
Fever on day 3 7 8 
C-reactive protein (mg/l)    
  at baseline: median (range) 100 (8–327)  1 128 (12–378) 1 
  at day 3: median (range) 59 (10–404) 75 (12–378) 
Bacterial urinary pathogens   
 Escherichia coli 73 64 
 Proteus spp. 1 1 
 Klebsiella pneumoniae 1 0 
 Enterococcus spp. 0 3 
 Data not available 5 6 
Positive blood cultures (E. coli) 0 1 
1
 p = 0.04, Mann-Whitney test 
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Table 2. Associated renal and urological anomalies 
 
 
Anomalies 
 
 
Oral 
n = 80 
 
 
Intravenous/oral group 
n = 72 
Vesico-ureteric reflux (VUR) 
 in patients1  
   unilateral 
   bilateral 
 in renal units2 
   left 
   right 
grade of VUR (renal units) 
 I - II 
 III 
 IV 
 
29  
  14 
  15 
44 (28%) 
  26 
  18 
 
  34 
    7 
    3 
 
35 
  21 
  14 
49 (34%) 
  29 
  20 
   
  37 
    8 
    4 
Hydronephrosis 1 0 
Hypospadia glandis 0 1 
Duplex kidney and ureterocele 1 0 
1
 p = 0.17; 2 p = 0.27 (comparison between the groups) 
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Table 3. Acute-phase lesions and scarring in renal units on DMSA scintigraphy 
 
Characteristics Oral group 
n = 160 
renal units 
 
Acute    Scarring 
Lesion 
Intravenous/oral 
n = 144 
renal units 
 
Acute     Scarring 
lesion 
adjusted 
p-
value* 
 
Renal units: acute lesions 
    Scarring 
        - Patients 
        - Renal units (% of all units) 
 
  881 
 
               21 
               21 (13%) 
 801 
 
              33 
              362 (25%) 
 
 
0.2 
0.5 
Renal units: acute lesion Grade I  49  29  
Scarring                4                3  
 
Renal units: acute lesion Grade II 
 
 28 
 
 29 
 
Scarring              11               13  
 
Renal units: acute lesion Grade III 
 
  9 
 
 17 
 
Scarring               5              15  
 
Renal units: acute lesion Grade IV 
 
  2 
 
  5 
 
Scarring               1               5 
 
 
1Eight patients in each group with acute-phase bilateral lesions; 2three patients with bilateral 
scarring.  
*p-values adjusted for CRP concentration at baseline and size of lesion on acute-phase  
 scintigraphy. 
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Table 4. Renal scarring and vesico-ureteric reflux 
 
 
Characteristics 
 
 
 
Oral group 
n = 80 
 
Intravenous/oral 
n = 72 
 
p-
value 
 
Scarring in patients with reflux 
 
 9/29 
 
18/35 
 
n.s. 
   “            without reflux 
 
12/51 15/37 n.s. 
 
All 152 patients 
Scarring in patients with reflux: 27/64 vs. without reflux: 27/88 
 
 
 
n.s. 
 
Scarring in renal units with ipsilateral reflux 
 All units 
 Left unit 
 Right unit 
 
 
 
  9/44 
  8/26 
  1/18 
 
 
  18/49 
  11/29 
   7/20 
 
 
n.s. 
 
All 304 renal units 
Scarring in units with reflux: 27/93 vs without reflux: 301 /211 
 
 
 
0.04 
1
 Three patients with bilateral scarring in non-refluxing units 
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Table 5. Renal scarring in patients with out-patient and in-patient management 
 
Management All patients Oral group  Intravenous/oral group 
 n Scars n Scars n Scars 
Out-patient  92 35 44 14 48 21 
In-patient 60 19 36 6 24 13 
χ2-test, p-value  0.5  0.2  0.3 
 
